Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 6
2001 4
2002 9
2003 2
2004 5
2005 5
2006 9
2007 3
2008 1
2009 5
2010 3
2011 2
2018 2
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Acute basophilic leukemia.
Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C. Giagounidis AA, et al. Among authors: aivado m. Eur J Haematol. 2001 Aug;67(2):72-6. doi: 10.1034/j.1600-0609.2001.t01-1-00487.x. Eur J Haematol. 2001. PMID: 11722593
Perspectives of proteomics in acute myeloid leukemia.
Czibere A, Grall F, Aivado M. Czibere A, et al. Among authors: aivado m. Expert Rev Anticancer Ther. 2006 Nov;6(11):1663-75. doi: 10.1586/14737140.6.11.1663. Expert Rev Anticancer Ther. 2006. PMID: 17134369 Review.
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Ng SY, et al. Among authors: aivado m. Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9. Nat Commun. 2018. PMID: 29789628 Free PMC article.
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, Sutton D, Olson KA, Packman K, Darlak K, Elkin C, Feyfant E, Kesavan K, Gangurde P, Vassilev LT, Nash HM, Vukovic V, Aivado M, Annis DA. Guerlavais V, et al. Among authors: aivado m. J Med Chem. 2023 Jul 27;66(14):9401-9417. doi: 10.1021/acs.jmedchem.3c00623. Epub 2023 Jul 13. J Med Chem. 2023. PMID: 37439511
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Carvajal LA, et al. Among authors: aivado m. Sci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003. Sci Transl Med. 2018. PMID: 29643228 Free PMC article.
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Walensky LD, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Saleh MN, et al. Among authors: aivado m. Clin Cancer Res. 2022 Jan 15;28(2):429. doi: 10.1158/1078-0432.CCR-21-4241. Clin Cancer Res. 2022. PMID: 35045962 Free PMC article. No abstract available.
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. Pairawan S, et al. Among authors: aivado m. Breast Cancer Res. 2021 Mar 4;23(1):29. doi: 10.1186/s13058-021-01406-x. Breast Cancer Res. 2021. PMID: 33663585 Free PMC article.
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Saleh MN, et al. Among authors: aivado m. Clin Cancer Res. 2021 Oct 1;27(19):5236-5247. doi: 10.1158/1078-0432.CCR-21-0715. Clin Cancer Res. 2021. PMID: 34301750 Free PMC article. Clinical Trial.
59 results